Rare diseases

Sharing the mission to conquer rare diseases

Closer collaboration between pharmaceutical companies and patient organizations will accelerate drug development At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases. Advocacy groups rely on their partners for financial and scientific support while providing access to repositories of patient data – the key to understanding rare diseases …

Early Drug Development: Rationale for an effective organization model.

At the 2014 Exploratory Clinical Development World Europe, Isabelle Paty, Head of Clinical Pharmacology/Early Drug Development, Ipsen, gave a presentation on “Early Drug Development: Rationale for an effective organization model.” Download and learn: Introduction: Ipsen as a mid- size Pharma Challenges for Early Drug Development Conclusion and perspectives Download Presentation. Found this interesting? Join us in 2015 for the 9th annual …

Whitepaper: The assessment of cognitive safety in compounds using cloud based clinical trial information systems throughout drug development

In this whitepaper, Dr Charlotte Housden, Cambridge Cognition, acknowledges the increasing pressure on pharmaceutical companies to accelerate the development of safe and effective treatments whilst reducing the risk of failure and encouraging commercial drug differentiation. In response to this growing demand, Cambridge Cognition has developed two cloud computing products to test cognitive safety and tolerability in drug development: Clinical Trial Information System – Profile …

Peter Milligan, Dr Nicholas Alp,drug development, integration, new technology, infographic, innovation congress

Infographic: Integrating new technology and processes to accelerate drug development

We’ve recently introduced new formats and new innovative ways to demonstrate the content given at our conferences. One of the latest introductions is the use of graphic reporting at our conferences. What’s a graphic reporter? A graphic reporter is someone who creates infographics concurrently with a presenter at the event – kind of like an interpreter, but with pictures. This …

30 mins, biosimilars, world

Around the Biosimilars World in 30 Minutes

At the Biosimilar Drug Development World Europe event 2014, Klaus Martin, Polpharma, gave a presentation on “Around the Biosimilars World in 30 Minutes” Klaus Martin’s presentation attempts to answer key questions such as  “Is there a biosimilars market? And Where?” “Where are we with naming of Biosimilars?” and  “How to get to biosimilarity?” Download and learn: Market themes Regulations Development IP Summary …

Download: What can we do to accelerate drug development?

  At last year’s Exploratory Clinical Development World Europe event, Massimo Bai, Global Head Clinical Pharmacology, UCB, gave a presentation entitled “What can we do to accelerate drug development?” Download and learn: Exploring valuable tools How (un)successful is drug development? Attrition rates grown…more late stages failures Better Understanding of Exposure, Occupancy, PD Modulation The challenging process of developing new drugs …

India’s Lupin queues up for a share of the biosimilar boom

Lupin is searching for partners to help bring it into the biosimilars market, aiming top-selling treatments with patents that are expiring soon. It already has 10 biosimilars products in development, with 5 in late-stage studies. Thus, it is looking for partners to help bring these products into the market. In addition to injectables for cancer and inflammatory disease, Lupin is …

US FDA Commissioner Margaret Hamburg met with Indian health regulators and pharma execs, saying she wanted to see more collaboration between FDA and Indian officials. However, India’s top drug regulator, G.N. Singh, the Drug Controller General of India, feels a little reluctant about adhering to all of FDA’s standards and expectations. He says that he sees some areas where the …

Singapore Fling: AbbVie says a plant in Asia is just what it needs

Abbvie, which spun off from Abbott Laboratories since early last year, has picked Singapore for the location of a new manufacturing plant to handle ingredients for small-molecule and biologic drugs for oncology and immunology drug candidates. According to Abbvie, this move could help alleviate the problem of decrease in revenue when Humira, its best-selling drug, goes off patent in 2016, …

Ovarian cancer biomarker could predict treatment response and help prevent metastasis

A research team from Case Western Reserve University in Ohio discovered a new microRNA biomarker, miR-181a, that may identify patients who will respond better to treatment for ovarian cancer and could serve as a drug target to prevent metastasis. Ovarian tumors are more likely to be resistant to chemotherapy with high levels of miR-181a, which in turn promotes metastasis by …